Page 180 of 1,034: studies 1,791 to 1,800 of 10,336, newest first. Back to the depression overview
JAMA Network Open May 1, 2023 R. Price, M. Wallace, S. Mathew et al. 9 citations
This secondary analysis of a randomized clinical trial examines whether automated self-association training can prolong the antidepressant effect of a single infusion of ketamine beyond 1 month in patients with treatment-resistant depression.
Behavioural Brain Research May 1, 2023 S. Kantor, Michael Lanigan, Lauren Giggins et al. 11 citations
Wistar-Kyoto (WKY) rats exhibit depression-like characteristics and decreased sensitivity to monoamine-based antidepressants, making them a suitable model of treatment-resistant depression (TRD). Ketamine has emerged recently as a rapidly acting antidepressant with high efficacy in TRD. Our aim was to determine whether subanaesthetic doses of ketamine can correct sleep and electroencephalogram...
Journal of Affective Disorders May 1, 2023 Guy M. Goodwin, Megan Croal, Lindsey Marwood et al. 13 citations
Blinding of treatment allocation in clinical trials in psychiatry is regarded as an ideal. The potential impact of unblinding chimes with a general concern for psychological research: so-called demand characteristics can undermine confidence in findings from experimental and clinical studies. Scepticism can result in nihilism. The reliance on subjective report of symptoms in clinical trials of...
Journal of Personalized Medicine April 29, 2023 Mujeeb U Shad
For the last 70 years, we did not move beyond the monoamine hypothesis of depression until the approval of the S-enantiomer of ketamine, an N-methyl-D-aspartate (NMDA) receptor blocker and the first non-monoaminergic antidepressant characterized by rapid antidepressant and antisuicidal effects. A similar profile has been reported with another NMDA receptor antagonist, dextromethorphan, which...
World Journal of Clinical Cases April 26, 2023 Jian Yang, Xin-Zhu Lin, Qian-Wen Guo et al.
Postpartum depression refers to a depressive episode or depressive symptoms up to 12 mo after delivery. Trait mindfulness has presented a protective factor for postpartum depressive symptoms and proved efficient in improving relationship satisfaction among couples. To investigate the correlations among mindfulness, marital quality, anxiety, and depression in a large city in western China during...
Psychological Medicine April 26, 2023
Abstract: While previous systematic reviews of trials evaluating conventional antidepressants highlighted inadequacies and inconsistencies in adverse event (AE) reporting, no evaluation is available on esketamine in resistant depression. The objective of this review was to assess quality of reporting AEs in all published clinical trials studying esketamine. It also aimed to compare the...
Journal of Psychopharmacology April 25, 2023 Brandon Weiss, David Erritzøe, Bruna Giribaldi et al. 24 citations
Background: In a recent clinical trial examining the comparative efficacy of psilocybin therapy (PT) versus escitalopram treatment (ET) for major depressive disorder, 14 of 16 major efficacy outcome measures yielded results that favored PT, but the Quick Inventory of Depressive Symptomatology, Self-Report, 16 items (QIDS-SR 16 ) did not. Aims: The present study aims to (1) rationally and...
Neuropsychopharmacology April 19, 2023 N. Murphy, Amanda J. F. Tamman, Marijn Lijffijt et al. 18 citations
Ketamine is an effective intervention for treatment-resistant depression (TRD), including late-in-life (LL-TRD). The proposed mechanism of antidepressant effects of ketamine is a glutamatergic surge, which can be measured by electroencephalogram (EEG) gamma oscillations. Yet, non-linear EEG biomarkers of ketamine effects such as neural complexity are needed to capture broader systemic effects,...
The International Journal of Neuropsychopharmacology April 17, 2023 Shokouh Arjmand, Marie Vadstrup Pedersen, N. Silva et al.
Abstract Background Recent preclinical and clinical studies have shed light on the possible impact of sex and estrous/menstrual cycle on ketamine’s antidepressant action but with incongruous results. The preclinical studies that have shown the effects of ovarian sex hormones have not done so in animal models of depression. Thus, the aim of the present study is to scrutinize the acute behavioral...
JAMA Oncology April 13, 2023 Manish Agrawal, Ezekiel Emanuel, Brian D. Richards et al. 48 citations
This nonrandomized controlled trial used a 1-to-1 therapist-to-patient ratio to administer psilocybin to groups of patients with cancer who were diagnosed with major depression disorder to create a scalable, rapidly effective depression treatment.